First-Line Switch to B/F/TAF for Treatment of HIV in Older Adults ≥60 Years in Kenya (the B/F/TAF-Elderly Study).

ABSTRACT:

Background

Older people living with HIV (PWH) are disproportionately affected by an increasing burden of comorbidities. There are few clinical trials of switching antiretrovirals in this population, particularly in Africa.

Methods

In this open-label randomized trial, virally suppressed PWH aged ≥60 years were randomized 1:1 to switch to bictegravir/emtricitabine/tenofovir alafenamide (B/F/TAF) or to continue their current antiretroviral regimen (CAR) at two sites in Kenya. Participants had bone mineral density (BMD) measurement at baseline, and at weeks 24 and 48. Calcium and vitamin D supplementation was provided to all participants beginning partway through the study because of high rates of osteoporosis identified at baseline. The primary endpoints were proportion of part

SUBMITTER: Ombajo LA 

PROVIDER: S-EPMC12631780 | biostudies-literature | 2025 Nov

REPOSITORIES: biostudies-literature